Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 10/20 | 0.61 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.61 |
| ▸ | CCR2 | P41597 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148508 | 0.99 | PYGL (0.62) | PYGLNHERF1CCR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2926379 | 0.98 | PYGL (0.61) | PYGLNHERF1CCR2MEN1KMT2A | |
| Iodide SCHEMBL17555143 | 0.91 | CCR2 (0.68) | PYGLNHERF1CCR2MEN1KMT2A | |
| SCHEMBL13148361 | 0.90 | CCR2 (0.69) | PYGLNHERF1CCR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL315416 | 0.89 | CCR2 (0.68) | PYGLNHERF1CCR2MEN1KMT2A | |
| Iodide SCHEMBL17555151 | 0.81 | PYGL (0.56) | PYGLNHERF1CCR2MEN1KMT2A | |
| Iodide SCHEMBL17555152 | 0.81 | PYGL (0.56) | PYGLNHERF1CCR2MEN1KMT2A | |
| SCHEMBL13148505 | 0.80 | PYGL (0.62) | PYGLNHERF1MEN1KMT2ARXFP1 | |
| Iodide SCHEMBL17555127 | 0.80 | CCR2 (0.59) | CCR2RXFP1 | |
| Iodide SCHEMBL5241769 | 0.80 | CCR2 (0.64) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1765803-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2006012135-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | PYGL 4506/4885NHERF1 467/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.